文献速递心脑血管急症重症综合管理与镇静镇痛

神经元特异性烯醇化酶(NSE)可改善心脏骤停患者神经功能预后和死亡预测的临床风险评分:一项前瞻性试验的结果

Neuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: Results from a prospective trial.
PubMed 文献 · Resuscitation · 2019-07-12
一句话结论心脏骤停后第3天NSE可显著提高CAHP和OHCA评分对神经功能预后及院内死亡的预测能力,可能辅助治疗升级或撤除的临床决策。

这项前瞻性观察研究纳入336例连续成人心脏骤停后患者,在ICU入院时计算OHCA评分和CAHP评分,并在入院时及第1、2、3、5、7天测量血清NSE。第3天NSE对神经功能预后(AUC 0.89)和院内死亡(AUC 0.88)的预测准确性最高,且可显著改善两种临床风险评分的判别能力(CAHP从AUC 0.81升至0.91;OHCA从AUC 0.79升至0.89)。以入院水平为基线的NSE动力学未进一步改善预测。作者认为第3天NSE可能有助于该脆弱人群的治疗升级或撤除决策。

要点

  • 心脏骤停后第3天NSE对神经功能预后预测准确性最高(AUC 0.89),对院内死亡预测AUC 0.88。
  • 第3天NSE显著改善CAHP评分判别能力:AUC从0.81升至0.91。
  • 第3天NSE显著改善OHCA评分判别能力:AUC从0.79升至0.89。
  • 以入院NSE为基线的动力学变化未进一步改善预后判断。
  • 336例患者中180例(54%)存活至出院,其中150例(45%)神经功能预后良好。

适用人群与场景

  • 连续纳入的成人心脏骤停后患者,收入ICU进行观察。

诊断标准与关键阈值

  • 神经功能预后采用脑功能表现分类(CPC)量表定义。
  • 计算OHCA评分和CAHP评分于ICU入院时。

研究设计与关键结果

  • 前瞻性观察研究纳入336例连续成人心脏骤停后患者,180例(54%)存活至出院,其中150例(45%)神经功能预后良好。
  • 第3天NSE对神经功能预后的判别能力最高(AUC 0.89),对院内死亡的判别能力AUC 0.88。
  • 第3天NSE显著改善CAHP评分的判别能力:AUC从0.81升至0.91。
  • 第3天NSE显著改善OHCA评分的判别能力:AUC从0.79升至0.89。
  • 以入院NSE水平为基线的NSE动力学未进一步改善预后判断。
  • 重分类统计和不同亚组中结果稳健。

证据类型、等级与局限

  • 证据类型:前瞻性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为第3天NSE可显著改善心脏骤停患者结局预测的临床风险评分,可能补充关于治疗升级或撤除的临床决策。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Neuron-specific enolase (NSE) increases in response to brain injury and is recommended for outcome prediction in cardiac arrest patients. Our aim was to investigate whether NSE measured at different days after a cardiac arrest and its kinetics would improve the prognostic ability of two cardiac arrest specific risk scores.

METHODS: Within this prospective observational study, we included consecutive adult patients after cardiac arrest. We calculated the Out-of-hospital cardiac arrest (OHCA) score and the Cardiac Arrest Hospital Prognosis (CAHP) score upon ICU admission and measured serum NSE upon admission and days 1, 2, 3, 5 and 7. We calculated logistic regression models to study associations of scores and NSE levels with neurological outcome defined by Cerebral Performance Category (CPC) scale and in-hospital death.

RESULTS: From 336 included patients, 180 (54%) survived until hospital discharge, of which 150 (45%) had a good neurological outcome. NSE at day 3 showed the highest prognostic accuracy (discrimination) for neurological outcome (area under the curve (AUC) 0.89) and in-hospital mortality (AUC 0.88). These results were robust in reclassification statistics and across different subgroups. NSE kinetics with admission levels serving as a baseline did not further improve prognostication. NSE on day 3 significantly improved discrimination of both clinical risk scores (CAHP from AUC 0.81 to 0.91; OHCA from AUC 0.79 to 0.89).

CONCLUSION: NSE measured at day 3 significantly improves clinical risk scores for outcome prediction in cardiac arrest patients and may thus add to clinical decision making about escalation or withdrawal of therapy in this vulnerable patient population.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Luescher T, Mueller J, Isenschmid C, et al. Neuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: Results from a prospective trial. Resuscitation. 2019. PMID: 31306716. doi:10.1016/j.resuscitation.2019.07.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。